share_log

Avenue Therapeutics | 424B5: Prospectus

Avenue Therapeutics | 424B5: Prospectus

Avenue Therapeutics | 424B5：募资说明书
美股sec公告 ·  05/10 16:55
Moomoo AI 已提取核心信息
Avenue Therapeutics, a specialty pharmaceutical company, has entered into a sales agreement with H.C. Wainwright & Co., LLC, dated May 10, 2024, to offer and sell up to $3,850,000 of its common stock. The common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI.' As of May 8, 2024, the closing sale price of Avenue's common stock was $4.40 per share. The sales agreement allows for the sale of shares through an 'at the market offering,' as defined by Rule 415(a)(4) under the Securities Act of 1933. H.C. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of Avenue Therapeutics. The Agent will receive a commission of up to 3% of the gross...Show More
Avenue Therapeutics, a specialty pharmaceutical company, has entered into a sales agreement with H.C. Wainwright & Co., LLC, dated May 10, 2024, to offer and sell up to $3,850,000 of its common stock. The common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI.' As of May 8, 2024, the closing sale price of Avenue's common stock was $4.40 per share. The sales agreement allows for the sale of shares through an 'at the market offering,' as defined by Rule 415(a)(4) under the Securities Act of 1933. H.C. Wainwright will act as a sales agent and will use commercially reasonable efforts to sell the shares on behalf of Avenue Therapeutics. The Agent will receive a commission of up to 3% of the gross proceeds from any sales made under the agreement. The sales agreement also includes indemnification and contribution provisions for certain liabilities. As of May 10, 2024, the public float of Avenue's common stock was approximately $11,600,000. The company is eligible to offer and sell shares of common stock up to approximately $3,850,000 under General Instruction I.B.6 of Form S-3. The prospectus supplement for this offering was dated May 10, 2024.
专业制药公司Avenue Therapeutics已于2024年5月10日与H.C. Wainwright & Co., LLC签订了销售协议，将发行和出售高达385万美元的普通股。普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。截至2024年5月8日，Avenue普通股的收盘售价为每股4.40美元。根据1933年《证券法》第415（a）（4）条的定义，销售协议允许通过 “市场发行” 出售股票。H.C. Wainwright将担任销售代理，并将采取商业上合理的努力代表Avenue Therapeutics出售股票。代理商将获得高达根据协议进行的任何销售总收益的3％的佣金。销售协议还包括...展开全部
专业制药公司Avenue Therapeutics已于2024年5月10日与H.C. Wainwright & Co., LLC签订了销售协议，将发行和出售高达385万美元的普通股。普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。截至2024年5月8日，Avenue普通股的收盘售价为每股4.40美元。根据1933年《证券法》第415（a）（4）条的定义，销售协议允许通过 “市场发行” 出售股票。H.C. Wainwright将担任销售代理，并将采取商业上合理的努力代表Avenue Therapeutics出售股票。代理商将获得高达根据协议进行的任何销售总收益的3％的佣金。销售协议还包括某些负债的赔偿和分摊条款。截至2024年5月10日，Avenue普通股的公开持股量约为11,600,000美元。根据S-3表格的I.B.6号一般指令，该公司有资格发行和出售不超过3850,000美元的普通股。本次发行的补充招股说明书的日期为2024年5月10日。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息